Pharma cos unfazed by US developments

THE INDIAN PHARMA industry is not worried about the possible benefits for Chinese biotech firms following the exclusion of the Biosecure Act, aimed at blacklisting them, from a key US defence budget Bill.

- MANU KAUSHIK

Domestic pharma players are betting on the Act, which still stands to blacklist five Chinese biotech firms from federally-funded research and contracts.

"The defence Bill doesn't override the Biosecure Act. Both Acts are independent of each other. We don't anticipate any adverse impact on the domestic pharma industry," said Viranchi Shah, national president, Indian Drugs Manufacturers Association.